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Abstract
Objective—To examine the use of existing practice control groups in randomized controlled
trials of behavioral interventions, and the role of extrinsic healthcare services in the design and
conduct of behavioral trials.
Method—Selective qualitative review.
Results—Extrinsic healthcare services, also known as nonstudy care, have important but under-
recognized effects on the design and conduct of behavioral trials. Usual care, treatment as usual,
standard of care, and other existing practice control groups pose a variety of methodological and
ethical challenges, but they play a vital role in behavioral intervention research.
Conclusion—This review highlights the need for a scientific consensus statement on control
groups in behavioral trials.
Keywords
control groups; delivery of health care; evidence-based medicine/methods; placebos; randomized
controlled trials as topic/methods; research design
INTRODUCTION
This article focuses on control groups that are used to contrast behavioral interventions with
existing treatments or healthcare practices. It also examines the effects of the extrinsic
healthcare environment on other aspects of randomized controlled trials (RCTs) of
behavioral interventions.
Historical Background
Across a vast assortment of disciplines and research domains, all clinical trialists are bound
by the same core methodological and ethical principles. However, distinctive traditions and
issues have emerged in different disciplines and research domains. Experimental psychology
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provided the methodological foundation for many early trials of behavioral interventions,
and it still exerts a profound influence on the design and conduct of behavioral RCTs.
Rigorous behavioral experiments were supposed to be conducted in tightly controlled
laboratories in which it could be guaranteed that an experimental manipulation was the only
difference between groups of subjects formed by random allocation. When it was discovered
that supposedly objective scientists could unintentionally bias the outcomes of their
experiments (1), psychological laboratory research methods became even more fastidious.
Because they emulated the methods of experimental psychology, many early clinical
behaviorists assumed that intervention research could and should be conducted in laboratory
environments or institutional settings that were well insulated from external influences. This
assumption pervaded many articles and textbooks on behavioral research methods (e.g., 2),
and it provided the principal rationale for laboratory analogue studies of behavior therapy.
(3) Early trials of systematic desensitization, contingency management, and other behavioral
interventions adhered as closely as possible to the ideals of laboratory research.(e.g., 4, 5)
A gradual shift away from laboratory-based behavioral intervention research began in the
late 1960’s, for several reasons. First, the generalizability of laboratory analogue studies was
questioned.(6) Second, Tharp and Wetzel’s influential book (7) argued that behavioral
interventions should be conducted in the recipient’s natural environment, to make the best
use of social resources and reinforcement contingencies. Finally, ecological validity became
a more salient consideration when behavioral researchers emerged from their laboratories to
investigate in vivo exposure and other treatments that had to be administered in the natural
environment.(8)
Psychotherapy researchers followed a different path to the same destination. Early
psychotherapy research consisted mostly of case studies, surveys, and observational studies.
It focused on psychotherapy as practiced in actual clinical settings, but it had serious
methodological limitations. This led some to conclude that laboratory analogue studies
could provide more rigorous evidence (9), but the need for greater ecological validity
ultimately prevailed. The most influential psychotherapy studies have been bona fide
treatment trials conducted in clinical settings (e.g., 10), not analogue experiments conducted
in laboratories.
However, the world outside the laboratory has turned out to be a rather complicated place in
which to conduct intervention research. Contemporary behavioral RCTs are embedded in an
elaborate matrix of healthcare environments and socioeconomic conditions. The medical and
mental health services that exist in the settings in which we conduct our trials and in the
communities from which we recruit our participants influence the kinds of control
conditions we can or cannot employ, and they affect our trials in many other ways as well.
Inescapable tradeoffs often have to be made between internal and external validity, and it is
not always possible to exercise tight control over every conceivable threat to either kind of
validity.(11) These challenges have grown along with the complexity of the healthcare
environments in which contemporary trials are conducted, but awareness of this aspect of
behavioral RCT methodology has not kept pace with these developments.
The Traditional Control Group Hierarchy
Many methodology texts (e.g., 12, 13, 14) present a hierarchy of traditional control
conditions that differ in stringency, i.e., in the magnitude of the impact that exposure to the
condition is designed or expected to have on the trial’s outcome variable(s). The least
stringent is a no-treatment control arm; the most is an active alternative treatment; and wait
list, attention, placebo, and treatment component control groups are in between. This
hierarchy has considerable heuristic value, but it is deficient in two respects.
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First, it obscures the distinction between the control and comparison functions of control
groups.(12) The primary purpose of most control groups is to control for threats to internal
validity (15), but active comparators also make it possible to determine whether an
experimental intervention is superior or inferior to some other form of treatment. Threats to
internal validity can often be controlled with conditions that are less stringent than active
comparators. All else being equal, it is more difficult to detect a treatment effect if an
intervention is compared to an active comparator than to a less stringent control condition.
(16) Because effect sizes are inversely related to control group stringency, trials with
relatively stringent controls require larger samples than trials comparing the same
intervention a less stringent control.(17) Consequently, researchers tend to use active
comparators only when comparison is a primary aim or external validity is a salient
consideration, such as in comparative effectiveness research.(18)
Second, the traditional hierarchy is based on the outmoded assumption that behavioral trials
can be isolated from the healthcare environments in which they are conducted. For example,
“no treatment” controls can only be used when it is possible to ensure that 1) the control
group participants are not given the experimental treatment, 2) they cannot obtain it from
any other provider, and 3) they cannot obtain any other treatment for the same problem. This
seldom holds true in any RCT in which the target is a physical or mental health problem and
the participants have access to nonstudy healthcare services, even if the services are
rudimentary.
The availability of nonstudy care scrambles the traditional control group hierarchy by
making it impossible to guarantee that ostensibly low stringency control conditions are
actually and uniformly less stringent than more active or intensive ones. For example, some
of the wait-listed participants in a behavioral intervention trial for insomnia may obtain
nonstudy hypnotics, even if the research team tries to dissuade them from doing so. The
higher the proportion of participants who take nonstudy medications, the less closely the
control condition approximates the textbook ideal of a wait list and the more it resembles an
active intervention.
Existing-Practice (EP) Comparison Groups
Existing practice control conditions are used to compare experimental interventions to
existing treatments or clinical practices. These conditions play an important role in medical
trials, and there is a growing literature on the challenges they pose.(19–25) They are also
playing an increasingly important role in behavioral trials, but little is said about them in
most behavioral research methodology textbooks. Nevertheless, there is growing interest in
the utility and pitfalls of EP control groups in behavioral research.(16, 26–32) The
characteristics of a variety of EP controls are summarized in Table 1.
Treatment as usual (TAU) control groups are used to compare experimental interventions to
treatments that are already used in clinical practice. The term “treatment as usual” seems to
imply that most patients with the target problem ordinarily receive a particular treatment, but
this is not always the case. “TAU” is used much more often to label EP control groups in
psychotherapy studies (33), mental health services research (26, 34), and behavioral
intervention trials for substance abuse (27) than in other areas of medical research.
Usual care (UC) is a roughly equivalent term that is used much more often than TAU in
medical trials and in behavioral medicine.(e.g., 35, 36, 37, 38) The term “usual care” does
not imply that patients ordinarily receive a specific treatment for the target problem. Instead,
it suggests a broader range of possibilities. For example, usual care for hypertension may
encompass a wide variety of drugs, nonpharmacological interventions, and clinical
monitoring. Like TAU, however, the term “usual care” does not always align with its
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broader connotations; sometimes, it actually does refer to a specific treatment.(19) Equally
ambiguous synonyms such as standard care (SC)(39, 40) or routine care (RC)(41, 42) are
occasionally used in trial reports instead of UC.
UC is a laissez faire condition in which healthcare providers who are independent of the
research team determine the participants’ care, but there are variants on UC that are
influenced by the research team. In an enhanced usual care (EUC) condition, usual care is
systematically improved by the research protocol to overcome ethical or methodological
problems that would accompany ordinary UC. The degree of enhancement can range from
minimal to extensive. The more extensively UC is enhanced, the less it approximates the
routine care that the participants would ordinarily receive if they were not involved in an
RCT, and the more it resembles an experimental intervention in its own right. EUC also
stretches the meaning of “nonstudy” care. To the extent that a trial protocol modifies any
aspect of the patient’s healthcare other than the specific treatment(s) being tested,
“nonstudy” care merges with “study” care. This applies not only to control groups, but to the
intervention arms of RCTs as well.
The Enhancing Recovery In Coronary Heart Disease (ENRICHD) trial provides an example
of a minimally enhanced usual care (mEUC) control group. All participants were given a
patient education booklet, and their personal physicians were informed if major depression
was diagnosed at baseline.(43) These enhancements addressed a potential confound
(between-group differences in secondary prevention education) and an ethical problem
(identifying but not treating major depression in the control group). The Pro-B Type
Natriuretic Peptide Outpatient Tailored Chronic Heart Failure Therapy (PROTECT) Study
provides an example an extensively enhanced usual care (eEUC) arm. All participants were
given guideline-adherent heart failure care. In some cases, this differed from the care they
received before enrollment in the trial.(44)
A second variant could be called constrained usual care (CUC), in which nonstudy care is
restricted in some way. For example, benzodiazepines may interfere with behavioral
interventions for anxiety disorders.(45, 46) Consequently, participants in a trial of a
behavioral treatment for panic disorder may be required to refrain from nonstudy
benzodiazepines.
A third variant is the standardized treatment regimen (STR), in which the same clinical care
or treatment(s) are administered in the same way to all participants. Standardization does not
necessarily mean that every patient receives identical treatment. Instead, each patient may be
treated according to a standardized protocol or care path.(22, 47, 48) STR presumably
differs from EUC and CUC in the extent to which treatment is homogenized. “Constraining”
care suggests that a particular ingredient of usual care is withheld, whereas “standardizing”
care implies more extensive calibration. Again, however, these sorts of terms are not always
used consistently or precisely.
In standard of care (SOC) control groups, participants receive state-of-the-art, evidence-
based, guideline-adherent clinical care. SOC is a naturalistic condition when patients are
recruited from settings that provide it routinely (e.g., specialty clinics at leading academic
medical centers). SOC may have to be imposed by enhancement of usual care when patients
are recruited from less stellar settings. If care is extensively enhanced or standardized in
order to provide the current standard of care, then eEUC, STR, and SOC may be
indistinguishable.
A uniform or protocol-driven standard of care (uSOC) produces the best clinical outcomes
for some conditions, but an individualized standard of care (iSOC) is best for others. Also,
some best practices are supported by strong evidence but others are not, and thus leave more
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room for expert judgment in clinical decision-making. Consequently, SOC control patients
are treated in a very uniform fashion in some trials but not in others.(19, 22)
The most problematic EP control condition might be called inadequate care (IC), reflecting
the inferior healthcare services to which underserved, uninsured, or captive patient
populations may be relegated. Whether it is ethically justifiable to compare a behavioral
intervention to IC depends on its translational potential.(49, 50) Hypothesized superiority to
IC, by itself, is an insufficient justification. The intervention should also be designed to help
close the gap between the target population’s inadequate care and that which is available to
more fortunate populations, and it should be potentially feasible to implement. Recent
studies of diabetes self-management (51) and multifactorial cardiovascular disease risk
reduction interventions (52) are examples of trials designed to improve upon IC for
underserved populations..
Two or more kinds of EP control conditions may be combined to produce a hybrid. For
example, UC may be enhanced in some ways but constrained in others. This could occur, for
instance, in a weight management trial in which UC is enhanced with health education
materials but constrained by prohibiting concurrent participation in other weight loss
programs.
Stringency and Uniformity in Existing Practice Control Groups
Like the traditional control groups, a stringency dimension underlies EP control conditions.
IC is the least stringent, and SOC is the most. To the extent that ordinary UC falls short of
the current standard of care, it is also less stringent than SOC.
Traditional control conditions are usually designed to be as uniform as possible. In a typical
placebo control group, for example, all participants are given the same placebo in exactly
the same manner. Some EP control conditions, such as STR, are also very uniform, but
others are not. There are several common sources of variability in EP controls. First,
nonstudy care may differ across participants because they receive healthcare services from
different providers, are covered by different insurance plans, or have different medical or
psychiatric problems.
Second, the quality of nonstudy care may differ across recruitment sites. For example, a
behavioral intervention trial for patients with heart disease might draw some participants
from a renowned specialty clinic at a major academic medical center and others from the
surrounding community. The quality of nonstudy care in these subgroups may be quite
different.
Third, routine practices and standards of care can change over time, as when widely-used
drugs fall into disfavor or new discoveries transform routine care in unanticipated ways. The
longer it takes to complete an RCT, the more likely it is that such developments will
introduce variability into EP control conditions.
Due to these sources of within-group variability, an RCT may be described as having a
certain kind of EP control condition, such as “usual care”, yet this descriptor can have very
different meanings for different participants. Also, it is common for hybrid control groups,
such as ones in which usual care is both constrained and enhanced, to simply be called UC
or TAU. Consequently, the labels that are affixed to EP control groups often oversimplify
the actual conditions to which the participants were exposed. In addition, if two trials have
“usual care” control groups, there may be little resemblance between the groups other than
their names.
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Stringency and uniformity are nearly orthogonal dimensions of EP control groups. The least
stringent IC control may be just as uniform in its paucity of care as the most stringent SOC
control group is in its excellence. Similarly, highly personalized and highly standardized
SOC control groups may be equally stringent. Whereas control group stringency tends to
reduce between-group differences in outcomes, control group uniformity may decrease
within-group variability and thereby increase between-group differences in outcomes.
Consequently, both dimensions can affect statistical power.
Standards of Care
A number of issues concerning standards of care can impinge on behavioral RCTs. First, the
treatment of a particular condition may be addressed in multiple clinical practice guidelines,
issued by different disciplines involved in the treatment of the same condition, for care
provided in different clinical settings or countries, or for care financed by different third-
party payers.(e.g., 53, 54, 55, 56, 57, 58) Consequently, operative standards of care may
depend on where a trial is conducted. In multicenter trials, standards of care may differ
across centers.
Second, in jurisdictions that operate under what is known as the locality rule, physicians and
other healthcare providers risk being held liable for malpractice if they adhere to national
standards of care rather than to local community standards.(59, 60) Most states now regard
the locality rule as anachronistic and have adopted national standards, but it is still in effect
in some states. It may be difficult to conduct trials with SOC control groups in these states,
with one notable exception: Federal facilities, such as Veterans Administration medical
centers, are required to adhere to their own national standards regardless of local standards.
Thus, behavioral trials conducted entirely within such facilities may be able to utilize true
SOC control groups.
Third, controversies about standards of care have arisen when RCTs have been conducted in
resource-poor countries. Some argue that it is unethical to conduct RCTs where local
standards of care fall far short of that which is widely available in wealthier countries.(61)
Others hold that prohibiting such trials would prevent tests of the very interventions that are
needed to improve treatment and prevention services in resource-poor regions.(62) In
practice, whether trials incorporate local levels of care or higher standards tends to differ
across conditions. For example, RCTs conducted in sub-Saharan Africa to test treatments for
tuberculosis tend to provide a high standard of tuberculosis care to control participants,
while trials targeting AIDS usually do not provide state-of-the-art HIV care to control
participants.(63)
Healthcare disparities within the United States (e.g., 64, 65) have raised concerns about
racial and socioeconomic disparities in clinical trial enrollment (66, 67) and about the
bioethics of recruiting medically underserved groups to participate in RCTs.(68) Much less
attention has been paid to racial, ethnic, gender, and socioeconomic disparities in the
nonstudy care that participants receive once they have been enrolled in clinical trials.
Nevertheless, such disparities undoubtedly contribute to variability in EP control groups.
Ubiquity of Nonstudy Care in Behavioral Trials
Nonstudy care is ubiquitous in the clinical research environments in which contemporary
behavioral trials are conducted. Its availability, quality, and effectiveness influence the self-
selection of patients into clinical trials, as well as the adherence and retention of participants
after trial enrollment.(69, 70) Nonstudy care is present in almost any control group that
might be employed in a behavioral trial, including both EP and traditional control
conditions. It is also present in most behavioral intervention arms as well. When participants
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in the intervention arm of a trial receive nonstudy care, it is often referred to as concomitant
therapy or co-intervention.(71, 72)
Nonstudy care is often overlooked when trial designs are described. For example, the design
of a trial comparing cognitive-behavioral pain management (CBPM) to progressive muscle
relaxation (PMR) would typically be presented as a comparison of CBPM vs. PMR.
However, a more accurate description would be (CBPM + UC) vs. (PMR + UC), because all
participants in the trial have access to nonstudy care. A report by Donta et al. (73) on a trial
of CBT and aerobic exercise provides an example of this approach.
The presence of nonstudy care in both arms of a trial does not necessarily mean that their
effects completely cancel each other out. Nonstudy alternatives may subtly influence the
delivery or acceptability of an experimental intervention, or modify its effects.
Hypothetically, if no other treatments for pain besides CBPM had ever been developed and
patients had no better recourse other than to try this experimental intervention, they would
be highly motivated to engage in the therapy and to adhere to the protocol. Of course, other
treatments for pain have been developed, and their availability through nonstudy channels
could affect the participants’ motivation to engage in CBPM. If PMR is a less burdensome
treatment, then it might be less permeable to this effect. This could create a subtle confound
that would be difficult to prevent and to detect. On the other hand, this effect would
strengthen the external validity of the findings, since CBPM and PMR can only be
implemented in a world in which other treatments for pain already exist.
Unblinded practitioners can also influence behavioral trial outcomes.(74) For example, in a
trial of cognitive behavior therapy (CBT) for depression, nonstudy physicians may be
informed about the group to which their patients have been assigned. They might be more
likely to prescribe nonstudy antidepressants to patients in the control group than to those in
the CBT arm.
Behavioral trialists know that nonstudy treatments for the primary target of their
experimental intervention can be problematic, both in intervention and in control arms.
Thus, if testing an intervention for anxiety, most investigators would be vigilant about
nonstudy treatment for anxiety. It is less widely understood that any form of nonstudy care
that can affect any of a trial’s outcomes, should be of concern. For example, a trial might be
conducted to test a novel intervention for anxiety in patients with breast cancer. Obviously,
nonstudy treatments for anxiety could affect the trial’s anxiety outcomes, but the nonstudy
treatment of cancer might also influence anxiety outcomes. Nonstudy treatments for medical
and psychiatric comorbidities could also affect anxiety. Furthermore, all of these aspects of
nonstudy care could affect secondary outcomes such as health-related quality of life.
If all aspects of a patient’s nonstudy care are potentially relevant, then it is necessary to
reconsider the meaning of “standard of care”. If this anxiety trial were conducted at a
leading center for cancer research, it would be safe to assume that the participants received
state-of-the-art, nonstudy cancer care. It would not necessarily follow that all of them also
received state-of-the-art, nonstudy care for anxiety, or for comorbidities such as diabetes
that might affect their anxiety or their health-related quality of life. A behavioral trial
probably should not be described as having an SOC control group unless the participants
received state-of-the-art care for the primary target of the intervention, which in this case
would be anxiety rather than cancer. However, if a medical variable such as time to cancer
recurrence or death were either a primary or a major secondary outcome of the trial, the
quality of nonstudy care both for anxiety and for cancer would be germane to the question of
what to call the control group.
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The broader relevance of nonstudy care also raises questions about how other EP control
conditions are defined in behavioral trials. For example, a recent article (27) described four
design options for effectiveness trials of behavioral interventions for substance abuse: 1)
new intervention vs. TAU; 2) new intervention + TAU vs. TAU; 3) new intervention + TAU
vs. alternative intervention + TAU; and 4) new intervention vs. standardized control
treatment. This is a very useful framework but it assumes that an identifiable TAU for
substance abuse is the only relevant aspect of nonstudy care. If one instead assumes that all
aspects of nonstudy care are potentially relevant, design #1 expands to (new intervention +
UC) vs. (TAU + UC), where TAU is whatever treatment is usually provided for substance
abuse in the community setting of interest, and UC covers all other aspects of nonstudy care,
such as for HIV, hepatitis C, smoking, or other health problems. The same logic applies to
the other designs.
Confounding and Mediation By Nonstudy Care
Enhancement and other systematic modifications of a control group’s nonstudy care can
confound a trial’s experimental variable unless comparable changes are made in the
intervention arm. However, this problem can be prevented at the design stage of an RCT.
For example, in the Heart Failure Adherence and Retention Trial (HART), there was
identical educational enhancement of nonstudy care in the intervention and control arms.
(75)
Behavioral trials can also be affected by post-randomization confounding and mediation.
Different arms can have different effects on the nonstudy care environment, resulting in
differential intensification or differential abatement of nonstudy care. If these are
unintentional effects, they constitute a form of post-randomization confounding that can bias
the trial’s outcomes. If they are deliberate, they are potential mediators of the effects of the
intervention.
Unintended differential intensification could occur, for example, in an RCT of a coping
skills intervention vs. UC for cancer survivors. Intervention participants may tell their
therapists about various signs, symptoms, and other health-related problems, whether or not
they are asked to do so. When therapists hear about new or worsening medical or psychiatric
problems, or ones that have not been adequately assessed or treated, they may advise
participants to call their nonstudy physician or take other appropriate actions. In
emergencies, they may take more active measures such as contacting the physician or
calling 911. These actions may intensify nonstudy care by promoting nonstudy physician
visits, hospital admissions, or more aggressive nonstudy medical treatment regimens, even
though the intervention is not designed or intended to produce such effects. UC participants
do not have therapists, so there are no comparable effects on their nonstudy care. If this
pattern of differential intensification occurs, the apparent effects of the intervention could
actually be due, at least in part, to nonstudy care.
The converse problem may occur if assessment staffers are not blinded to group assignments
and are not in equipoise about the treatment and control conditions. In this circumstance,
they may encourage more nonstudy care in the UC than in the intervention arm, out of
concern that control group members are not getting any therapeutic help from the trial. This
could work against the trial’s hypothesis and increase the risk of a Type II error. Efforts to
blind the research staff and to instill therapeutic equipoise can help to counteract this
potential source of bias.
A recent trial of two different treatments for opioid addiction in adolescents provides an
example of a study in which possible confounding by nonstudy care was examined. Woody
and colleagues (76) found that significantly fewer participants in their extended
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buprenorphine-nalaxone plus counseling arm obtained nonstudy addiction care during the
trial than did the participants in the standard detoxification plus counseling arm. This
effectively ruled out unintentional differential intensification of nonstudy addiction
treatment as a rival explanation for the superior outcomes observed in the experimental
treatment group.
This is a relatively rare example; few other behavioral RCT trial reports have included
secondary analyses that might have revealed or ruled out post-randomization confounding
by differential intensification of nonstudy care, even when differences in utilization of
nonstudy care have been identified.(e.g., 77) Consequently, the prevalence of this potential
threat to the internal validity of behavioral RCTs is unknown. It might be common, or it
might not be. The only way to find out is for behavioral trialists to start collecting the
requisite data.
Differential intensification of nonstudy care is a deliberate strategy in some behavioral trials.
For example, in the Matching Alcoholism Treatments to Client Heterogeneity (Project
MATCH) trial, participants were randomly assigned to CBT, motivational enhancement
therapy (MET), or Twelve-Step Facilitation (TSF). The aim of TSF was to increase
participation in Alcoholics Anonymous (AA), a type of non-study intervention. As intended,
AA involvement was significantly higher in the TSF than in the other two arms. There were
no significant between-group differences in any other form of nonstudy care.(78) In this
example, nonstudy intervention (AA) was designed to mediate rather than confound the
relationship between the TSF intervention and alcoholism outcomes.
Deliberate intensification resembles deliberate enhancement of nonstudy care, but they are
not synonymous. Deliberate intensification is implemented only in the treatment arms of
trials of disease management, collaborative care, and other interventions that work in
conjunction with nonstudy care. In contrast, deliberate enhancements of nonstudy care are
implemented in both arms of most EUC-controlled trials. Also, deliberate intensification is
an experimental procedure, and the principle of equipoise requires uncertainty as to whether
the intervention will actually succeed in intensifying nonstudy care or whether doing so will
improve clinical outcomes. In contrast, deliberate enhancement is designed to improve
nonstudy care in ways that will make it a more suitable comparator than ordinary UC or IC,
and there should be little uncertainty as to whether the enhancements will be both feasible
and beneficial.
Differential abatement of nonstudy care can also be a deliberate strategy. For example,
Allen et al. (79) randomly assigned patients with somatization disorder to standard medical
care augmented by a psychiatric consultation intervention or to a manualized cognitive-
behavioral treatment program that was added to the psychiatric consultation intervention and
designed to decrease somatization and healthcare utilization. Compared to the control group,
the CBT group had significantly greater improvements in self-reported functioning and
somatic symptoms and a greater decrease in nonstudy healthcare service utilization.
It may not be possible to completely prevent post-randomization confounding, and it would
not be desirable to prevent intentional mediation by nonstudy care. Thus, it is necessary to
document and analyze any elements of nonstudy care that could affect the trial’s outcomes.
Unfortunately, there is little guidance on this subject in the behavioral RCT literature, and
few examples to follow. Much of the literature on treatment intensification has focused on
clinical care, not on clinical trials. For example, there have been several studies of clinical
inertia, which is defined as the failure of physicians or other healthcare providers to initiate
or intensify therapy when indicated, e.g., when a diabetes patient’s glycemic control starts to
deteriorate, or when a first-line antidepressant fails to produce remission.(80–83) Other
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studies have evaluated various methods for measuring treatment intensification in clinical
practice.(84) A number of recent collaborative care studies (e.g., 36, 85) have included basic
measures and analyses of nonstudy treatment intensification, because it is one of the explicit
aims of the intervention.
In behavioral trials, any recommendations, referrals, or other actions taken by study staff
that could impinge on nonstudy care should be systematically documented. This would
include, for example, occasions when research staffers ask participants questions such as,
“Have you told your doctor about that?”, give more directive advice such as, “You should
call your doctor right away about that,” or intervene directly, e.g., “I’m calling 911.” The
documentation should classify the action (recommendation, referral, or direct intervention)
and the agent (e.g., interventionist, research staff, or investigator). However, it can be hard
to link such actions to actual changes in nonstudy care. For example, if a counselor advises a
patient to talk to his doctor about a new symptom and the patient does so, an outpatient visit
may or may not follow, and it might take place long after the advice was given. It might be
difficult to connect these dots, but in some trials, it might be worth the effort to do so.
Differences between groups in the quality of nonstudy care can also pose a threat to internal
validity. Published, evidence-based clinical guidelines can be converted into checklists and
completed to assess key aspects of the quality of nonstudy care received by participants in
both the intervention and control arms of an RCT. For example, a checklist based on the
American Heart Association’s guidelines for the management of chronic, stable angina (86)
could be developed to assess the quality of nonstudy cardiac care in a trial of stress
management for patients with angina pectoris. It is likely to be impractical to
comprehensively assess every available quality indicator that might be relevant to a trial, so
checklists should probably be limited to ones that are based on strong evidence from
multiple RCTs or rigorous meta-analyses (e.g., Class Ia/Ib recommendations). The checklist
data can be used to determine whether groups differ in the receipt of guideline-adherent
nonstudy care during the trial. The data can also be used to characterize the quality of care
received by the study sample as a whole. Consistent collection of such data would enable
meta-analysts to evaluate whether the quality of nonstudy care moderates the effects of
behavioral interventions.
Choosing Control Conditions for Behavioral Trials
Given the challenges that EP control groups can pose, one might wonder why they should
ever be used in behavioral RCTs. However, they are indispensible in randomized
effectiveness trials that evaluate whether new interventions can replace or augment existing
practices.(27) They also have an important place in behavioral efficacy research. Indeed, the
omnipresence of nonstudy care blurs the distinction between efficacy and effectiveness
trials. Behavioral efficacy and effectiveness studies generally do not differ as to whether
they are conducted in “real world” settings, but instead in the kinds of real world settings
where they take place. Whether a clinical trial is conducted at a university teaching hospital
or at a rural community health clinic, it involves real patients, real health problems, and real
nonstudy healthcare services.
Efficacy and effectiveness trials do tend to differ as to whether the primary goal of the
research is explanatory (e.g., to advance understanding about an intervention or to determine
whether an experimental treatment and a comparator produce different outcomes) or
pragmatic (e.g., to support policy decisions about which treatments to use in clinical
practice).(87) EP control conditions play an important role not only in pragmatic research,
but in explanatory trials as well. The pervasive presence of nonstudy care often makes it
imperative to utilize EP controls in behavioral efficacy studies. It can also eliminate the
option of using traditional control groups, at least in pure form. For example, it may not be
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possible to expose control participants only to a placebo, to the exclusion of nonstudy care.
Furthermore, existing practices are key determinants of whether it is considered ethical to
employ traditional controls. Ethical concerns about placebo controls typically do not revolve
around any harm that the placebo itself might cause, but focus instead on the risks of
depriving patients of established therapies.(88)
As another example, a treatment development trial testing whether a novel intervention has
any effect at all cannot employ a pure no-treatment control condition if nonstudy care is
available. The closest approximation may be a UC control group in which participants
receive no additional intervention besides their usual nonstudy care. Constrained usual care
may be another alternative in some instances. The PREMIER trial, for example, tested the
efficacy of lifestyle behavior and dietary interventions in individuals with prehypertension
or stage 1 hypertension. The participants were not taking antihypertensive medications at
enrollment and they were not given such medications during the intervention phase.(89, 90)
Control group stringency generally increases as research progresses from early treatment
development work to definitive efficacy trials.(16) This holds not only for traditional control
groups but for EP controls as well. For example, an intervention might be compared initially
to ordinary UC. Even if the results are positive, they may not change clinical practice
because the UC participants did not receive state-of-the-art therapy. If the next trial
demonstrates superiority to a more rigorous SOC control, it could have a greater impact.
On the other hand, some trials are not undertaken with the goal of surpassing the current
SOC or a well-established treatment. Their aim is instead to demonstrate the efficacy of a
more practical or cost-effective alternative to an existing intervention or SOC that is too
expensive, intensive, or inaccessible for the target population.(91, 92) For example,
telephone-delivered interventions have been tested for depressed patients who are too
medically ill, immobilized, time challenged, or distant from standard clinical services to be
able to attend psychotherapy sessions in person. Similarly, internet-based lifestyle behavior
interventions have been tested as alternatives to direct clinical services.(93, 94) Is the
appropriate comparison for such interventions a nationally-established SOC to which the
participants lack routine access? Or is it the local UC or IC that represents their de facto
standard of care? The answer is debatable, like it has been in other controversies that have
arisen where there are marked disparities in nonstudy healthcare services.
Explanatory trials designed to test biobehavioral mediation hypotheses are another exception
to the rule that advanced stages of research should employ relatively stringent controls. Such
trials aim to determine whether treatment of a behavioral or psychosocial problem improves
medical outcomes. The goal is not to test the practical efficacy of the intervention but rather
to test the hypothesis that the behavioral or psychosocial problem is a causal risk factor, not
merely a risk marker, for the medical outcome. The success of the trial depends on
producing the largest possible between-group difference in the behavioral or psychosocial
outcome. This makes it highly desirable to choose an intervention with established efficacy
for changing the behavioral or psychosocial outcome, along with the least stringent control
that is possible and ethical to employ. Given the aims of these studies, it would be
counterproductive to use more stringent control conditions or to design them as if they were
pragmatic efficacy trials.
For example, ENRICHD was an explanatory trial designed to determine whether treatment
of depression and inadequate social support decreases the risk of myocardial infarction or
death in patients with coronary disease.(43) It was not a pragmatic trial of the efficacy of
CBT for depression or inadequate social support. Its mEUC control group was the least
stringent comparator that was both feasible and ethical to use. It would have been
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counterproductive to employ a more stringent eEUC or SOC control, or an attention or
placebo control group.
Equipoise and Existing Practice Controls
The bioethical principle of equipoise has been vigorously debated (95–97), but there is
consensus that RCTs should be conducted only when there is significant uncertainty about
what will be found. Researchers typically initiate a superiority trial because they believe that
an experimental intervention may be superior to some alternative, but they should not do so
if its superiority is almost inevitable, as this would violate the principle of equipoise. Efforts
to adhere to this principle can also help to reduce experimenter bias in RCTs that cannot be
double-blinded, in which there is always a risk that the deck will somehow be stacked, even
if inadvertently, in favor of the experimental intervention. This is just as important a concern
in EP-controlled trials as it is when traditional control conditions are employed in behavioral
RCTs.
Research in England on community-based interventions for severely mentally ill individuals
provides a cautionary lesson. The existing practice in the U.K. has long been for care to be
provided by community mental health teams (CMHTs). An alternative approach known as
Assertive Community Treatment (ACT) was tested in a series of studies, most recently by
Killaspy et al.(98) ACT is more intensive and expensive than CMHT, but favorable findings
in early trials led to substantial public investment in ACT implementation. Subsequent
research found that ACT produces no better outcomes than CMHT in terms of the most
important indicators, particularly hospitalization rates. After reviewing this line of research,
Burns (28) argued that researchers and policy-makers might have been able to reach this
conclusion many years sooner if CMHT had been viewed all along as an active comparator,
rather than being framed as a presumptively inferior “treatment-as-usual” control condition.
Labeling these trials as randomized comparisons of ACT vs. TAU, and failing to specify the
latter condition as rigorously as the former, may have conveyed an assumption that ACT
was the superior approach, thereby creating an implicit bias. Framing them instead as
randomized trials of ACT vs. CMHT might have fostered greater neutrality and minimized
inadvertent biases in favor of ACT.
Attention, Expectancy, and Existing Practice Controls
A common concern about EP control conditions is that they do not eliminate differential
attention and expectancies as threats to internal validity.(99, 100) This issue deserves careful
scrutiny. If the aim of a trial is to determine whether an intervention is superior to existing
practices, then it has to be compared to those practices. Controlling for attention entails
exposing control group participants to some sort of clinical experience that takes as much
time and provides as much contact with a therapist as the intervention. Thus, a three-arm
trial ([intervention + UC] vs. [attention + UC] vs. [UC alone]) would be needed to achieve
the trial’s primary aim while also controlling for attention and expectancy. Three arms are
more expensive than two, and they expose more patients to experimentation. The question is
whether the attention arm is necessary.
In a drug efficacy trial, the aim is to determine the effects of a specific chemical compound.
The most important rival explanations are the placebo effect and clinical attention. Neither is
plausible for some drugs (e.g., general anesthetics), but both are quite plausible for others
(e.g., antidepressants).(101) To control for these twin threats to internal validity, patients are
randomly assigned in double-blind fashion to drug or placebo. The groups are given equal
attention, typically in the form of clinical management.(102) Thus, clinical management is
co-administered with medication or placebo. The Sertraline Antidepressant Heart Attack
Randomized Trial (SADHART) is an example of this type of trial.(103)
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In many psychotherapy efficacy studies, the primary aim is to determine whether an
intervention’s putative active ingredients yield incremental benefits over those of its
nonspecific ingredients, which are also known as common factors. Attention is a nonspecific
ingredient of any psychotherapeutic or behavioral intervention that involves human
therapists, but it cannot be distilled and delivered in pure form by having therapists sit and
stare at control group participants for the same amount of time that treatment group
therapists spend with theirs. Clinical attention inevitably must be wrapped in a credible
intervention. Thus, attention control groups in psychotherapy trials require two ingredients,
i.e., clinical attention and an intervention that induces an expectation of therapeutic benefits,
much like drug trial control groups combine clinical attention with pill placebos.
For example, a psychotherapy trial comparing two interventions to a supportive therapy
control group was cited in a recent methodology textbook as an excellent example of an
attention/placebo control design.(13) The supportive therapy did control for common
factors, but it also helped patients express their feelings and identify options for addressing
personal problems.(104) Clearly, it provided something more than content-free clinical
attention.
The aim of some behavioral trials is to compare the efficacy of different dosages of the same
therapy. For example, Edinger et al. (105) conducted an RCT to compare CBT for insomnia,
delivered in 1, 2, 4, or 8 sessions over an 8-week period. In such trials, the amount of
clinical attention is the experimental variable and it differs between groups by design. In
other trials, the aim to compare the efficacy or effectiveness of two (or more) different
treatments for the same problem. There is often an effort in such trials to hold attention
constant across groups, and to statistically adjust if necessary for differential attention, so
that differences in outcomes can be attributed to differences in the putative active
ingredients of the interventions. In a recent trial, for example, Safran et al. (106) compared
CBT to relaxation with educational support for residual symptoms of attention-deficit/
hyperactivity disorder (ADHD) in medication-treated adults. Both groups received 12
weekly, 50-minute sessions.
In many trials, however, differentiating between specific and nonspecific ingredients is not a
priority. If the goal is to push the envelope of efficacy and achieve better outcomes by
whatever means seem most promising, rather than to disaggregate a particular intervention,
it may be unnecessary to control for attention but a UC or SOC control group may be
essential. The same intervention can be studied in different trials for different reasons, and
control conditions that are optimal for some of these trials may be unsuitable for others. The
paramount consideration in choosing a control condition is how well it fits the purpose of
the trial.(107)
The assumption that it is always necessary to control for attention in psychotherapy or
behavioral intervention trials rests on the questionable premise that attention is always a
threat to internal validity. It is a genuine threat to the internal validity of standard drug trials
because they are designed to answer questions about chemical compounds, not about their
clinical delivery. Psychotherapy differs from pharmacotherapy in that clinical attention is an
integral component of psychotherapy, not something that is co-administered with it.
Attention is not a rival explanation for the effects of psychotherapy; it is an indispensible
ingredient of psychotherapy. Since attention can only be delivered in the guise of a credible
intervention, comparison rather than control is the primary function of an attention control
group in a behavioral RCT.
If an RCT shows that a novel intervention is superior to UC, critics might dismiss the
findings because they could be partially due to an imbalance in the amount of clinical
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attention that was given to the two groups. In response, one might ask, “So what? Why does
that matter?” The intervention cannot be delivered without attention, so what difference does
it make how much of its effect is due to attention? A more important question is whether
comparable clinical outcomes can be achieved with a less expensive or intensive
intervention, like the kind that might be employed in an “attention control” group. That,
however, is a comparative effectiveness study for another day, and there may never be a
need for it unless the intervention is first shown to be superior to usual care.
A landmark depression trial by DeRubeis and colleagues (108, 109) provides an example of
a well-designed RCT in which controlling for attention was not a high priority. The primary
purpose of the trial was to compare cognitive therapy to antidepressant therapy. A placebo
control group was included because the comparison between the two active arms would
have been difficult to interpret unless it was confirmed that the antidepressant was superior
to placebo.(110) Both the placebo and the active medication participants received less
clinical attention than the cognitive therapy participants. This was an appropriate design
decision, because the medication and placebo arms received as much clinical attention as
was consistent with the current “best practices” for antidepressant pharmacotherapy, and
because the main purpose of the study was to compare the efficacy of the active
interventions, not to parse their specific and nonspecific ingredients.
Participants’ outcome expectations play an important role in clinical trials. If two groups are
assigned to different treatments but have identical outcome expectations, then any
differences in outcomes are not attributable to differential expectations. This is the
foundation of the double-blind, placebo-controlled RCT design. With rare exceptions,
behavioral trials cannot be double-blinded, so they have to be conducted without the
protection against differential expectancies that double blinding is designed to provide. If
two groups in a behavioral RCT differ both with respect to a treatment variable (e.g., one
group receives counseling and the other receives usual care) and to outcome expectations,
then differential expectations confound the treatment variable and can complicate the
interpretation of the trial’s results.
Few behavioral RCT reports have included data on participant expectations, and even fewer
have systematically investigated differential expectations as a rival explanation for the trial’s
outcome. There has been more research on the effects of treatment preferences in behavioral
RCTs. Treatment preferences are strongly influenced by expectations of benefit, although
there are other determinants as well, such as concerns about potential risks, side effects, and
exposure to novel or experimental interventions.(111–113) Some studies have found little or
no difference in outcomes between groups that are randomly assigned to treatments and ones
that are assigned according to patient preference, or between groups in which treatment
assignments are matched or mismatched to patient preferences.(112, 114–117) However,
others have shown that outcome expectations and treatment preferences can have significant
effects on trial outcomes. In one study, for example, primary care patients with major
depression who chose counseling had better outcomes than those who were randomized to it
(118, 119), and the outcomes in several RCTs have differed between participants who were
matched to their preferred treatment and those who were mismatched.(119–122) Despite
these inconsistent findings, it is safe to conclude that expectancy and preference effects
should be taken into account in planning and conducting behavioral RCTs, including but not
limited to ones that employ EP control conditions.
However, controlling patient expectations is easier said than done. This is evident, for
example, in the highly variable placebo response rates that dozens of antidepressant trials
have yielded among patients with major depression (101), in controversies that have arisen
concerning the magnitude of placebo effects in many other trials (123–127), and in the
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surprising efficacy of “open label” placebos.(128) Participant expectations are influenced by
multiple inputs, only some of which are determined by the study’s design or procedures. For
example, expectations of benefit depend on the number of active and/or placebo arms in
double-blinded RCTs.(129–131) A variety of other inputs, such as the patient’s past
experiences with similar treatments, are not determined by anything that the trialist does or
fails to do.(132)
Participants have idiosyncratic expectations about their nonstudy care, just as they do about
whatever treatment (if any) a trial exposes them to. Individual differences in expectancies
can arise even under highly standardized conditions in double-blinded comparisons of
equally credible treatments (133), and variability in nonstudy care can widen these
differences. No matter which type of control group one chooses, and no matter how
diligently one tries to equilibrate expectancies, they can still differ within and between
groups. Thus, although equivalent expectancies are desirable, they cannot be guaranteed and
should not be required when planning behavioral trials.
Differential expectancies may arise when behavioral interventions are compared to existing
practices, but this should not preclude the use of EP controls. Whatever steps can be taken to
minimize these differences should be taken, as long as they are compatible with the trial’s
aims. Investigators should not assume that participants will necessarily prefer or expect
greater benefit from an experimental intervention than they do from usual care. There are a
variety of reasons why some participants’ expectancies and preferences may not favor the
treatment arm in a behavioral RCT. For example, some patients may have more confidence
in their own personal physician’s advice about managing behavioral or emotional problems
than they do in an unfamiliar study therapist into whose care they are randomly assigned.
Others may consent to participate in an RCT for altruistic reasons, or for remuneration; in
either case, they may prefer usual care because it is less burdensome than participation in the
treatment arm.
Questionnaires should be used in behavioral trials to systematically assess expectancies and
treatment preferences. The resulting data should be used in secondary analyses to evaluate
the role of expectancies and of matched or mismatched preferences in the trial’s outcomes.
(100, 112, 123) Routine inclusion of these analyses in behavioral RCT reports would
strengthen the quality of the evidence that we generate.
Conclusions and Recommendations
Behavioral trialists have to weigh a variety of scientific, ethical, practical, and other
considerations in choosing control groups for their RCTs. If nonstudy care is present in the
clinical trial environment, it may not be possible to control for every conceivable threat to
internal validity, at least not in a single trial. Consequently, it may be necessary to control
for whichever threats are judged to be the most important, at the expense of remaining
vulnerable to less important ones. It is not always possible to give equal weight to internal
and external validity in designing a trial when nonstudy care is available. It is not always
ethical to employ a traditional control group if doing so would deprive participants of
treatments that have already been incorporated into routine clinical care. In short, difficult
tradeoffs often have to be made in choosing a control or comparison group for a behavioral
trial. Existing practices and nonstudy care are what make many of these tradeoffs so
difficult. On the other hand, existing practice comparison groups such as UC or SOC play
invaluable roles in behavioral trials. Some of the most important goals of behavioral
intervention research could not be achieved without them.
This article has highlighted a number of issues that have received relatively little attention in
the behavioral trial literature, but that are sources of uncertainty and disagreement among
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investigators, reviewers, bioethicists, and behavioral research methodologists. The best way
to address these issues would be to develop an evidence-based scientific consensus
statement or guideline on control groups in behavioral RCTs. We recommend that a
consensus task force be created that would adhere to current standards for evidence-based
guidelines.(134) This would help to accelerate progress in numerous areas of behavioral
research.
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Glossary
CUC constrained usual care
EP existing practice
EUC enhanced usual care
eEUC extensively enhanced usual care
HIV human immunodeficiency virus
IC inadequate care
iSOC individualized standard of care
mEUC minimally enhanced usual care
PMR progressive muscle relaxation
RC routine care
RCT randomized controlled trial
SC standard care
SOC standard of care
uSOC uniform standard of care
STR standardized treatment regimen
TAU treatment as usual
UC usual care
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TABLE 1
Existing Practice Control Groups





      Inadequate Care (IC) Inaccessible or poor quality nonstudy care Low Trial-
Dependent
Low
      Treatment As Usual (TAU),
      Usual Care (UC),
      Routine Care (RC), or
      Standard Care (SC)
Typical, normative, nonstudy care Moderate Trial-
Dependent
High
      Standard of Care (SOC)
            Individualized (iSOC) Individualized, state-of-the-art, guideline-adherent
nonstudy care
High Low Low




      Standardized treatment regimen
      (STR)
Nonstudy care is standardized for the trial to ensure





      Constrained Usual Care (CUC) Specific aspects of usual nonstudy care are withheld





      Enhanced Usual Care (EUC)
            Minimally Enhanced (mEUC) Nonstudy care is enhanced in minor ways during the





            Extensively Enhanced (eEUC) Nonstudy care is substantially enhanced during the
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